The role of live influenza vaccines in children

Vaccine

Volumn 20, Issue SUPPL. 2, 2002, Pages

  Gruber, William C ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

Children; Efficacy; Influenza; Live influenza vaccine

Indexed keywords

ANTIBODY; HEMAGGLUTININ; IMMUNOGLOBULIN A; INFLUENZA VACCINE; TRIPLE VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; SIALIDASE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ASSOCIATION; ATTENUATION; CLINICAL TRIAL; CONFERENCE PAPER; DOCUMENTATION; DRUG EFFECT; DRUG EFFICACY; GENETIC STABILITY; HEMAGGLUTINATION INHIBITION; HUMAN; INFECTION COMPLICATION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; NONHUMAN; NOSE; OTITIS MEDIA; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROVOCATION TEST; SERUM; VIRUS STRAIN; WORK; ARTICLE; BLOOD; CHILD; CLASSIFICATION; GENETIC REASSORTMENT; GENETICS; IMMUNOLOGY; ORTHOMYXOVIRUS; VACCINATION;

ANTIBODIES, VIRAL; CHILD; CLINICAL TRIALS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMAN; INFLUENZA; INFLUENZA VACCINE; NEURAMINIDASE; ORTHOMYXOVIRIDAE; REASSORTANT VIRUSES; VACCINATION; VACCINES, ATTENUATED; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 0037095579     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00141-X     Document Type: Conference Paper

References (59)

1. Interpandemic influenza in the Houston area, 1974-1976
2. Influenza B virus infections in the community and the family. The epidemics of 1976-1977 and 1979-1980 in Houston, Texas
3. Comparison of infection rates and severity of illness for influenza A subtypes H1N1 and H3N2
4. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
5. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia
6. Adaptation and growth characteristics of influenza virus at 25 °C
7. Sequence comparisons of A/AA/6/60 influenza viruses: Mutations which may contribute to attenuation
8. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children
9. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children
10. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: Safety, immunogenicity and dose-response
11. Effect of age on cytotoxic T-lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine
12. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses
13. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live attenuated viruses
14. Live attenuated influenza A virus vaccines in children: Results of a field trial
15. Comparison of long-term systemic and secretory antibody responses in children given live attenuated or inactivated influenza A vaccine
16. Simultaneous administration of live attenuated influenza A vaccines representing different serotypes
17. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus
18. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease
19. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985-1990: The pediatric experience
20. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: Safety, immunogenicity and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group
21. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children
22. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine
23. Determination of antibody response to influenza virus surface glycoproteins by kinetic enzyme-linked immunosorbent assay
24. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children
25. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally
26. Correlates of immune protection induced by live attenuated, cold-adapted, trivalent, intranasal influenza virus
27. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children
28. Anatomy of an urban influenza epidemic
29. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of school children
30. Herd immunity following subunit influenza vaccine administration
31. The Japanese experience with vaccinating schoolchildren against influenza
32. Effectiveness of live attenuated intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial
33. Molecular and biological changes in the cold-adapted master strain A/AA/6/60 (H2N2) influenza virus
34. Cold-adapted recombinant influenza A virus vaccines in seronegative young children
35. Genetic stability of A/Ann Arbor/6/60 cold-mutant (temperature-sensitive) live influenza virus genes: Analysis by oligonucleotide mapping of recombinant vaccine strains before and after replication in volunteers
36. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial
37. Safe administration of the measles vaccine to children allergic to eggs
38. Safe administration of influenza vaccine to patients with egg allergy
39. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: Results of a 3-year study
40. Immunization of institutionalized asthmatic children and patients with psychomotor retardation using live attenuated cold-adapted reassortment influenza A H1N1, H3N2 and B vaccines
41. Evaluation of live attenuated influenza vaccine safety and immunogenicity in children with asthma
42. A randomized, double-blind, placebo-controlled trial of the safety, transmissibility and phenotypic stability of a live attenuated, cold-adapted influenza virus vaccine (CAIV-T) in children attending day care
43. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus
44. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness
45. Avian-to-human transmission of H9N2 subtype influenza A viruses: Relationship between H9N2 and H5N1 human isolates
46. Emergence of avian H1N1 influenza viruses in pigs in China
47. Cocirculation of avian H9N2 and contemporary human H3N2 influenza A viruses in pigs in southeastern China: Potential for genetic reassortment?
48. Infection of children with avian-human reassortant influenza virus from pigs in Europe
49. Genetic reassortment between avian and human influenza A viruses in Italian pigs
50. Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated from pneumonia patients in The Netherlands
51. Human influenza A (H1N2) viruses isolated from China
52. Origin and evolutionary characteristics of antigenic reassortant influenza A (H1N2) viruses isolated from man in China
53. Laboratory-based surveillance of influenza virus in the US during the winter of 1977-1978. Part II. Isolation of a mixture of A/Victoria- and A/USSR-like viruses from a single person during an epidemic in Wyoming, USA, January 1978
54. Simultaneous administration of live attenuated influenza A vaccines representing different serotypes
55. Phenotypic expression of HA-NA combinations in human-avian influenza A virus reassortants
56. Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans
57. Trials of influenza A/New Jersey/76 virus vaccine in normal children: An overview of age-related antigenicity and reactogenicity
58. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children - A multicentered evaluation of dosage and safety
59. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine